- Previous Close
339,500.00 - Open
335,000.00 - Bid 331,500.00 x --
- Ask 332,000.00 x --
- Day's Range
328,500.00 - 346,500.00 - 52 Week Range
107,000.00 - 356,500.00 - Volume
82,647 - Avg. Volume
104,366 - Market Cap (intraday)
3.47T - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield 1,100.00 (0.33%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
321,444.44
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.
pharmaresearch.co.krRecent News: 214450.KQ
View MorePerformance Overview: 214450.KQ
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 214450.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 214450.KQ
View MoreValuation Measures
Market Cap
3.47T
Enterprise Value
3.05T
Trailing P/E
37.52
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.86
Price/Book (mrq)
6.43
Enterprise Value/Revenue
8.70
Enterprise Value/EBITDA
22.73
Financial Highlights
Profitability and Income Statement
Profit Margin
26.29%
Return on Assets (ttm)
11.33%
Return on Equity (ttm)
17.23%
Revenue (ttm)
350.12B
Net Income Avi to Common (ttm)
92.04B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
437.35B
Total Debt/Equity (mrq)
36.62%
Levered Free Cash Flow (ttm)
67.22B